Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors

Haugnes, Hege Sagstuen; Oldenburg, Jan; Bremnes, Roy M.

doi:10.1016/j.urolonc.2014.11.012

Cited by 51 publications

(33 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this sense, experimental studies directed to the identification and understanding of the mechanisms involved in this particular toxicity could be useful to the scientific community. In the present study, the experimental conditions used provoked in the animals, cardiovascular alterations similar to those described in humans treated with cycles of cisplatin (Demkow and Stelmaszczyk-Emmel, 2013; Haugnes et al, 2015; Herrmann et al, 2016), being a useful tool for this purpose. However, further investigations are needed to identify early signs of cardiac and vascular damage in order to optimize the clinical management of cardiotoxicity in cisplatin treatments.…”

Section: Resultsmentioning

confidence: 85%

Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments

et al. 2017

View full text Add to dashboard Cite

In the last years, many clinical studies have revealed that some cisplatin-treated cancer survivors have a significantly increased risk of cardiovascular events, being cisplatin-induced cardiovascular toxicity an increasing concern. The aim of the present work was to evaluate the cardiovascular alterations induced by different chronic cisplatin treatments, and to identify some of the mechanisms involved. Direct blood pressure, basal cardiac (left ventricle and coronary arteries) and vascular (aortic and mesenteric) functions were evaluated in chronic (5 weeks) saline- or cisplatin-treated male Wistar rats. Three different doses of cisplatin were tested (1, 2, and 3 mg/kg/week). Alterations in cardiac and vascular tissues were also investigated by immunohistochemistry, Western Blot, and or quantitative RT-PCR analysis. Cisplatin treatment provoked a significant modification of arterial blood pressure, heart rate, and basal cardiac function at the maximum dose tested. However, vascular endothelial dysfunction occurred at lower doses. The expression of collagen fibers and conexin-43 were increased in cardiac tissue in cisplatin-treated rats with doses of 2 and 3 mg/kg/week. The expression of endothelial nitric oxide synthase was also modified in cardiac and vascular tissues after cisplatin treatment. In conclusion, chronic cisplatin treatment provokes cardiac and vascular toxicity in a dose-dependent manner. Besides, vascular endothelial dysfunction occurs at lower doses than cardiac and systemic cardiovascular toxicity. Moreover, some structural changes in cardiac and vascular tissues are also patent even before any systemic cardiovascular alterations.

show abstract

Section: Resultsmentioning

confidence: 85%

Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The main cause is probably a continuous development of late effects of TGCT treatment, for which both direct and indirect mechanisms, such as the metabolic syndrome, have been suggested (1)(2)(3). Supporting this is the striking difference between RS curves of localized malignant melanoma and TGCT (Fig.…”

Section: Discussionmentioning

confidence: 90%

“…The notion that survivors of testicular germ cell tumors (TGCT) have a normal life expectancy is being challenged (1). Despite today's excellent 10-year survival rates of above 95%, TGCT treatment is associated with an increased risk of potentially life-threatening late effects.…”

Section: Introductionmentioning

confidence: 99%

“…Despite today's excellent 10-year survival rates of above 95%, TGCT treatment is associated with an increased risk of potentially life-threatening late effects. The most important are second malignant neoplasms and cardiovascular disease, usually manifesting beyond 10 years of follow-up (1)(2)(3)(4)(5)(6)(7)(8). Even more alarming are the reports on increased mortality from these and other conditions in TGCT survivors (1-4, 9, 10).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor

Kvammen

Myklebust

Solberg

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Long-term relative survival (RS) data for testicular germ cell tumor (TGCT) patients are scarce. We aimed to analyze long-term RS among TGCT patients diagnosed in Norway, between 1953 and 2012.Methods: Data sources were the Cancer Registry of Norway and the Norwegian Cause of Death Registry. TGCT patients diagnosed during 1953 to 2012 were classified by time of diagnosis, histology, age, and disease extent at diagnosis. Estimates for RS were obtained, and a test comparing overall RS was performed. Corresponding data were obtained for men diagnosed with localized malignant melanoma before age 50.Results: A total of 8,736 TGCT patients were included. RS generally continued to decline with increasing follow-up time, particularly beyond 15 to 30 years, unlike in localized malignant melanoma. Although RS was generally higher for seminomas, the continuing decline was more pronounced than for nonsemino-

show abstract

“…Consistent clinical follow‐up of TC patients must also observe possible therapy‐related (late) side effects, including cardiovascular disease, metabolic syndrome, hypogonadism, and secondary tumours (Einhorn et al, ; Fung, Fossa, Milano, Oldenburg, & Travis, ; Haugnes, Oldenburg, & Bremnes, ; Willemse et al, ). Patients treated with chemotherapy or radiotherapy have a considerably increased risk of secondary tumours and cardiovascular events.…”

Section: Discussionmentioning

confidence: 99%

Testicular cancer guideline adherence and patterns of care in Germany: A nationwide survey

Nestler

Baunacke²,

Dräger

et al. 2018

Eur J Cancer Care

View full text Add to dashboard Cite

Testicular cancer has excellent cure rates; however, poor guideline adherence can lead to inappropriate management, with a detrimental effect on outcomes. Therefore, we aimed to investigate the current patterns of care for testicular cancer patients and to evaluate guideline adherence. A 19‐item survey was distributed among German urologists between September 2015 and September 2016. The response rate was 45% (411/920). Staging imaging of the chest was performed by computed tomography (CT) in 85.5% and X‐ray in 17.7%, and for the abdomen, by CT in 83.7% and by magnetic resonance imaging (MRI) in 21.1%. Areas of discrepancy with respect to guideline recommendations included underuse of MRI and infrequent follow‐up examinations for changes in the cardiovascular, endocrine, neurological, and pulmonary systems, in addition to psychological burden. Further deviations of reported routine procedures from guideline recommendations were identified in the fields of active surveillance in Stage I seminoma, contralateral biopsies (63.1% overuse) and cryopreservation (19.2% underuse). Moreover, we found that hospital‐based clinicians and younger specialists, with ≤5 years of practice following board certification, perform a more accurate and thorough follow‐up. German urologists show relatively strong guideline adherence in staging patterns. Significant improvements are necessary in the following areas: recommending cryopreservation, imaging modalities and accurate follow‐up examinations with a focus on late toxicities.

show abstract

Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors

Cited by 51 publications

References 80 publications

Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments

Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments

Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor

Testicular cancer guideline adherence and patterns of care in Germany: A nationwide survey

Contact Info

Product

Resources

About